Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Chronic Hepatitis B Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for chronic hepatitis B has been experiencing consistent growth in the past few years. The growth is projected to escalate from $3.77 billion in 2024 to $3.94 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.5%. This historic period growth rate ties back to enhancements in antiviral treatment methods, the increment in initiatives by both the government and non-profit organisations, advancements in diagnostic procedures, the amplified instances of HIV, and heightening awareness.

What Is the Forecast for the Chronic Hepatitis B Market Size Through 2029?

The market for chronic hepatitis B is projected to experience a consistent growth rate in the coming years with an estimated value of $4.65 billion by 2029 and a compound annual growth rate (CAGR) of 4.2%. Factors contributing to this predicted growth during the forecast period include the expansion in emerging markets, escalating government policies and funding, advancements in diagnostics and screening, increased healthcare expenditure, rising strategic alliances and partnerships, an increase in the elderly population, and extensive public awareness campaigns. Key trends anticipated during this period include a move towards curing therapies, the growth of emerging markets, superior diagnostic and screening methods, collaborations and partnerships, and an emphasis on patient-focused care.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

What are the Key Market Players in Chronic Hepatitis B Market and How They’re Evolving?

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

What Are the Primary Growth Drivers in the Chronic Hepatitis B Market?

The chronic hepatitis B virus market is anticipated to expand due to the growing trend of chronic hepatitis B infections. Hepatitis B, a liver infection caused by the hepatitis B virus (HBV), can be prevented by vaccination. The swell in hepatitis B infections is attributed to various elements, especially in countries with lower to middle incomes where insufficient vaccination programs result in greater transmission rates. As large demographics remain unarmed against the virus, the requirement for diagnostic tests and treatments multiplies. As detailed in a report from the Centers for Disease Control and Prevention (CDC), a U.S based government agency, in 2024, enhancing worldwide hepatitis B vaccination to 90% and medical accessibility to 80% could deter 26 million novel infections and 9 million deaths from hepatitis B from 2022 to 2050. In 2022, there was a count of 1.2 million fresh hepatitis B virus (HBV) infection cases. Consequently, the rise in hepatitis B infection rates will fuel the expansion of the chronic hepatitis B virus market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp

What Are the Leading Segments in the Global Chronic Hepatitis B Industry?

The chronic hepatitis B market covered in this report is segmented –

1) By Drug Class: Antivirals, Immune Modulators

2) By Gender: Male, Female

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)

2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)

What Are the Key Market Trends in the Chronic Hepatitis B Industry?

In the field of chronic hepatitis B, top players are prioritizing novel technologies such as advanced antiviral treatments. These cutting-edge therapies are drug innovations that specifically target viral infections, particularly drug-resistant ones, by stalling their replication process and utilizing sophisticated delivery systems, while also undergoing safety and effectiveness trials, like that of bepirovirsen. GSK plc, a UK multinational pharmaceutical and biotechnology company with expertise in the development, production, and marketing of diverse healthcare products, received FDA Fast Track status for its investigational drug, bepirovirsen, aimed at treating chronic hepatitis B in February 2024. Bepirovirsen is engineered to target and break down the hepatitis B virus RNA, potentially allowing the immune system to regain control of the infection. During the Phase IIb trials, more specifically in the B-Clear and B-Sure studies, the drug displayed optimal results by lowering hepatitis B surface antigen levels and achieving sustained viral suppression.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

What Is the Regional Outlook for the Chronic Hepatitis B Market?

North America was the largest region in the chronic hepatitis B market in 2023. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17112

This Report Delivers Insight On:

1. How big is the chronic hepatitis b market, and how is it changing globally?

2. Who are the major companies in the chronic hepatitis b market, and how are they performing?

3. What are the key opportunities and risks in the chronic hepatitis b market right now?

4. Which products or customer segments are growing the most in the chronic hepatitis b market?

5. What factors are helping or slowing down the growth of the chronic hepatitis b market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model